Spyre Therapeutics annual shares outstanding
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Spyre Therapeutics Shares Outstanding History (SYRE)
Spyre Therapeutics reported 78.2M shares outstanding at the end of fiscal 2025.
View full Spyre Therapeutics company overviewSpyre Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 78.2M | 17.9M | +29.76% |
| 2024 | 2024-12-31 | 60.3M | 24.2M | +67.12% |
| 2023 | 2023-12-31 | 36.1M | 33.4M | +1279.38% |
| 2022 | 2022-12-31 | 2.6M | −46.7M | −94.70% |
| 2021 | 2021-12-31 | 49.4M | 1.4M | +2.91% |
| 2020 | 2020-12-31 | 48.0M | 18.9M | +64.90% |
| 2019 | 2019-12-31 | 29.1M | 4.9M | +20.48% |
| 2018 | 2018-12-31 | 24.1M | 7.5M | +44.81% |
| 2017 | 2017-12-31 | 16.7M | 3.2M | +24.12% |
| 2016 | 2016-12-31 | 13.4M | 13.4M | +18567.70% |
| 2015 | 2015-12-31 | 71,946.92 | — | — |
Spyre Therapeutics quarterly shares outstanding
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 88.1M | 27.7M | +45.87% |
| Q1 2026 | 2026-03-31 | 78.8M | 18.6M | +30.80% |
| Q4 2025 | 2025-12-31 | 78.2M | 17.9M | +29.76% |
| Q3 2025 | 2025-09-30 | 60.5M | 9.1M | +17.66% |
| Q2 2025 | 2025-06-30 | 60.4M | 9.6M | +18.88% |
| Q1 2025 | 2025-03-31 | 60.3M | 23.6M | +64.55% |
| Q4 2024 | 2024-12-31 | 60.3M | 24.2M | +67.12% |
| Q3 2024 | 2024-09-30 | 51.4M | 47.3M | +1169.44% |
| Q2 2024 | 2024-06-30 | 50.8M | −30.2M | −37.31% |
| Q1 2024 | 2024-03-31 | 36.6M | −28.8M | −43.99% |
| Q4 2023 | 2023-12-31 | 36.1M | −29.3M | −44.82% |
| Q3 2023 | 2023-09-30 | 4.0M | −57.5M | −93.42% |
| Q2 2023 | 2023-06-30 | 81.0M | 19.8M | +32.42% |
| Q1 2023 | 2023-03-31 | 65.4M | 16.0M | +32.33% |
| Q4 2022 | 2022-12-31 | 65.4M | 16.0M | +32.41% |
| Q3 2022 | 2022-09-30 | 61.5M | 12.2M | +24.75% |
| Q2 2022 | 2022-06-30 | 61.2M | 12.1M | +24.78% |
| Q1 2022 | 2022-03-31 | 49.4M | 399,972 | +0.82% |
| Q4 2021 | 2021-12-31 | 49.4M | 1.4M | +2.91% |
| Q3 2021 | 2021-09-30 | 49.3M | 4.6M | +10.32% |
| Q2 2021 | 2021-06-30 | 49.0M | 4.4M | +9.92% |
| Q1 2021 | 2021-03-31 | 49.0M | 19.9M | +68.18% |
| Q4 2020 | 2020-12-31 | 48.0M | 18.9M | +64.90% |
| Q3 2020 | 2020-09-30 | 44.7M | 15.8M | +54.52% |
| Q2 2020 | 2020-06-30 | 44.6M | 15.8M | +54.60% |
| Q1 2020 | 2020-03-31 | 29.1M | 310,109 | +1.08% |
| Q4 2019 | 2019-12-31 | 29.1M | 4.9M | +20.48% |
| Q3 2019 | 2019-09-30 | 28.9M | 6.8M | +30.88% |
| Q2 2019 | 2019-06-30 | 28.8M | 6.9M | +31.68% |
| Q1 2019 | 2019-03-31 | 28.8M | 12.0M | +71.55% |
| Q4 2018 | 2018-12-31 | 24.1M | 7.5M | +44.81% |
| Q3 2018 | 2018-09-30 | 22.1M | 20.5M | +1312.10% |
| Q2 2018 | 2018-06-30 | 21.9M | 20.3M | +1301.71% |
| Q1 2018 | 2018-03-31 | 16.8M | 15.5M | +1215.35% |
| Q4 2017 | 2017-12-31 | 16.7M | 15.4M | +1206.51% |
| Q3 2017 | 2017-09-30 | 1.6M | 1.4M | +1191.05% |
| Q2 2017 | 2017-06-30 | 1.6M | 1.6M | +13492.28% |
| Q1 2017 | 2017-03-31 | 1.3M | 1.3M | +2071642.79% |
| Q4 2016 | 2016-12-31 | 1.3M | 1.3M | +2068342.88% |
| Q3 2016 | 2016-09-30 | 121,213.268 | — | — |
| Q2 2016 | 2016-06-30 | 11,498.918 | — | — |
| Q1 2016 | 2016-03-31 | 61.685 | — | — |
| Q4 2015 | 2015-12-31 | 61.685 | — | — |
Spyre Therapeutics shares outstanding trends
Over the last five reported fiscal years, Spyre Therapeutics's shares outstanding moved from 48.0M to 78.2M, a change of 30.2M. The latest reported quarter, Q2 2026, shows 88.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spyre Therapeutics filings at SEC.gov ↗